VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 µM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 µM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002)[1].
Molekulargewicht:
298.33
CAS Nummer:
[110763-24-1]
Formel:
C21H14O2
Target-Kategorie:
Androgen Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten